--- title: "ProPhase Labs (PRPH) news: convertible notes" url: "https://aibio.space/companies/prophase-labs/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PRPH convertible notes news: ProPhase Labs issues $2,085,000 senior secured convertible note. ProPhase Labs, Inc. (OTC: PRPH), United States." --- PRPH ProPhase Labs, Inc. OTC · United States # ProPhase Labs (PRPH) news PRPH convertible notes news Mergers · 2026-09-17 ## [Impact BioMedical reports Zoar F-4 filing in business combination](https://aibio.space/news/impact-biomedical-reports-zoar-f-4-filing-business-combination/) Zoar Limited filed a Form F-4 on September 10, 2026 that includes Impact BioMedical's preliminary proxy statement for the proposed business combination with Zoar Labs Limited. ## Latest ProPhase Labs news 1. 2026-07-31 Debt Financing [ProPhase Labs issues $2,085,000 senior secured convertible note](https://aibio.space/news/prophase-labs-issues-2-085-000-senior-secured-convertible-note/) ProPhase Labs signed a senior secured convertible loan with J.J. Astor & Co. on July 31, 2026. The note has an original principal of $2,085,000, a funding amount of $1,440,000 and a final maturity of July 31, 2027. ## ProPhase Labs at a glance - **Ticker**: PRPH - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $20,000 ### Related companies - [ACCURAY INC](https://aibio.space/companies/accuray/) NASDAQ: ARAY - [Pulmonx](https://aibio.space/companies/pulmonx/) NASDAQ: LUNG - [MiniMed Group](https://aibio.space/companies/minimed/) NASDAQ: MMED - [Harvard Apparatus Regenerative Technology](https://aibio.space/companies/harvard-apparatus-regenerative-technology/) OTC: HRGN - [VIVOS INC](https://aibio.space/companies/vivos/) OTC: RDGL - [biote](https://aibio.space/companies/biote/) NASDAQ: BTMD - [Curaleaf Holdings](https://aibio.space/companies/curaleaf/) OTC: CURLF - [Charlie's Holdings](https://aibio.space/companies/charlie-s/) OTC: CHUC ### Also on OTC - [SQZ Biotechnologies](https://aibio.space/companies/sqz-biotechnologies/) SQZB - [Cresco Labs](https://aibio.space/companies/cresco-labs/) CRLBF - [NIKA PHARMACEUTICALS, INC](https://aibio.space/companies/nika-pharmaceuticals/) NIKA - [Avenir Wellness Solutions](https://aibio.space/companies/avenir-wellness-solutions/) AVRW - [MULTICELL TECHNOLOGIES INC](https://aibio.space/companies/multicell-technologies/) MCET - [Kaleido Biosciences](https://aibio.space/companies/kaleido-biosciences/) KLDO ## What ProPhase Labs does ProPhase Labs, Inc. describes itself as a diversified biotech, genomics and consumer products company. It develops and commercializes novel drugs, dietary supplements and compounds, and offers human genomic testing. Its subsidiary DNA Complete, with sequencing performed at Nebula Genomics, sells whole genome sequencing products direct to consumers online, with plans to sell in food, drug and mass retail stores and to provide testing for universities conducting genomic research. DNA Complete offers ancestry and personalized health reports. The company's BE-Smart test is an esophageal pre-cancer diagnostic screening test that is still under development, aimed at early detection of progression from Barrett's esophagus to esophageal adenocarcinoma. The company plans to commercialize it as a Laboratory Developed Test. The company also markets dietary supplements under the TK Supplements brand. Its COVID-19 testing subsidiary, ProPhase Diagnostics, has not provided diagnostic testing services since the fourth quarter of 2024, and its entities filed voluntary Chapter 11 petitions in September 2025 in the United States Bankruptcy Court for the District of New Jersey. | Product or program | What it is | Stage | |---|---|---| | BE-Smart Esophageal Pre-Cancer test | Screening test for progression from Barrett's esophagus to esophageal adenocarcinoma | Under development | | DNA Complete whole genome sequencing | Direct-to-consumer genomic tests with Essential, Pro and Elite tiers | Offered direct to consumers online | | DNA Expand | Platform for uploading prior DNA data to obtain health and wellness reports | Offered | | TK Supplements | Dietary supplements | Marketed | Summarised from the company's [10-K filed Jun 1, 2026](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/prph-20251231.htm). ## ProPhase Labs annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$4.3 million](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | [$6.8 million](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | | Research and development | [$107,000](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | [$594,000](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | | Net income (loss) | [-$14.7 million](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | [-$53.4 million](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | | Cash from operations | [-$8.3 million](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | [-$17.5 million](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | | Cash and equivalents | [$90,000](https://www.sec.gov/Archives/edgar/data/868278/000149315226039224/) | [$678,000](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | [$3.1 million](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $20,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ProPhase Labs Has ProPhase Labs sold convertible notes? Our latest story on this, dated Jul 31, 2026: "ProPhase Labs issues $2,085,000 senior secured convertible note". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/prophase-labs-issues-2-085-000-senior-secured-convertible-note/). What is the ticker symbol of ProPhase Labs? ProPhase Labs, Inc. trades under the ticker PRPH on OTC. Where is ProPhase Labs listed? ProPhase Labs, Inc. is listed on OTC. Which country or territory is ProPhase Labs listed under? Our directory records ProPhase Labs, Inc. under United States. Does aibio.space cover ProPhase Labs? aibio.space lists ProPhase Labs, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does ProPhase Labs develop? ProPhase Labs, Inc. describes itself as a diversified biotech, genomics and consumer products company. It develops and commercializes novel drugs, dietary supplements and compounds, and offers human genomic testing. What is BE-Smart Esophageal Pre-Cancer test from ProPhase Labs? BE-Smart Esophageal Pre-Cancer test: Screening test for progression from Barrett's esophagus to esophageal adenocarcinoma Stage: Under development. What is DNA Complete whole genome sequencing from ProPhase Labs? DNA Complete whole genome sequencing: Direct-to-consumer genomic tests with Essential, Pro and Elite tiers Stage: Offered direct to consumers online. What was ProPhase Labs's revenue last year? $4.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is ProPhase Labs profitable? ProPhase Labs, Inc. reported a net loss of $14.7 million for the fiscal year ended Dec 31, 2025, and used $8.3 million of cash in operations, per its annual report to the SEC. How much does ProPhase Labs spend on research and development? $107,000 in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does ProPhase Labs have? $20,000 in cash at Jun 30, 2026, per its 10-Q. What is the latest ProPhase Labs (PRPH) stock news? Our latest story on ProPhase Labs, dated Jul 31, 2026: "ProPhase Labs issues $2,085,000 senior secured convertible note". ProPhase Labs signed a senior secured convertible loan with J.J. Astor & Co. on July 31, 2026. The note has an original principal of $2,085,000, a funding amount of $1,440,000 and a final maturity of July 31, 2027. [Source](https://aibio.space/news/prophase-labs-issues-2-085-000-senior-secured-convertible-note/). Which other companies' news mentions ProPhase Labs? ProPhase Labs is named in 1 of our story about other companies, most recently: "Impact BioMedical reports Zoar F-4 filing in business combination" (Sep 17, 2026). [Source](https://aibio.space/news/impact-biomedical-reports-zoar-f-4-filing-business-combination/). How can I follow ProPhase Labs (PRPH) news? Press Follow on this page to add ProPhase Labs to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming ProPhase Labs so far, in Debt Financing, Mergers. ## Investor discussion: ProPhase Labs Members talk about ProPhase Labs (PRPH). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ProPhase Labs, newest first. Each line links the filing it comes from. 1. 2026-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/868278/000149315226038433/formnt10-q.htm) 2. 2026-06-01 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/868278/000086827826000005/prph-20251231.htm) 3. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/868278/000149315226023848/formnt10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:PRPH on TradingView](https://www.tradingview.com/symbols/OTC-PRPH/). ## Listing details ProPhase Labs, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker PRPH, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ProPhase Labs, Inc. - **Ticker**: PRPH - **Listing**: OTC - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/prophase-labs/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ProPhase Labs (PRPH) news: convertible notes", 2026-10-31, https://aibio.space/companies/prophase-labs/